Skip to main content
SpringerLink
Log in

The basis for current treatment recommendations for malignant gliomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Although primary brain tumors represent an important cause of cancer related mortality in the United States, advances in the treatment of these tumors has been slow and has generally lagged behind that of most systemic tumors. One of the major reasons for this is the paucity of well conducted, prospective radiation and chemotherapy trials. For the brain tumor trials that have been conducted, small patient numbers, heterogeneous patient populations, and non-uniformity of response criteria, have made the current clinical data base difficult to interpret. Data from several prospective, multi-institutional randomized trials have defined a role for radiation therapy in the treatment of malignant gliomas and on-going trials will help define refinements in technique. Although there does appear to be a place for the use of chemotherapy in the treatment of a subgroup of patients with malignant gliomas, its role for the majority of patients remains unclear. Only through better understanding of the biology of these tumors, more effective therapies, and the implementation of better clinical trial design can we hope to make significant progress in the treatment of malignant gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E, Lubera JA: Cancer statistics 1989 Ca 39: 3 (Comment in CA 39: 254, 1989 and Comment in Ca 39: 399, 1989). 1989

    Google Scholar 

  2. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: The national survey of intracranial neoplasm. Neurology 35: 219, 1985

    PubMed  Google Scholar 

  3. Green JR, Waggener JD, Kriegsfeld BA: Classification and incidence of neoplasms of the central nervous system. Adv Neurol 15: 51, 1976

    PubMed  Google Scholar 

  4. Ammirati M, Vick N, Liao YLet al.: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytomas. Neurosurgery 21: 201–206, 1987

    PubMed  Google Scholar 

  5. Leibel SA, Scott CB, Pajak TF: The management of malignant gliomas with radiation therapy: therapeutic results and research strategies. Sem in Rad One 1: 32–49, 1991

    Google Scholar 

  6. Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Cancer Treat Rev 16: 129–160, 1989

    Google Scholar 

  7. Zelen M: Theory and practice of clinical trials. In: Holland JF, Frei E III, Bast RC, Kufe DW, Marten DL, Weichselbaum KR (eds) Cancer Medicine. Lea & Febiger, Philadelphia 2: 340–360, 1993

    Google Scholar 

  8. Group EBCTC: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. One hundred thirty-three randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1 (part 1); 85 (part 2), 1992

    Google Scholar 

  9. Eagan RT, Scott M: Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J Clin Oncol 1: 38–44, 1983

    PubMed  Google Scholar 

  10. Nelson JS, Tsukada Y, Schoenfeld Det al.: Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas. Cancer 53: 550–5541, 1983

    Google Scholar 

  11. Nelson DF, Nelson JS, Davis DRet al.: Survival and prognosis of patients with astrocytomas with atypical or anaplastic features. J Neuro-Oncol 3: 99–103, 1985

    Google Scholar 

  12. Deutsch M, Green SB, Strike TAet al.: Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16: 1389–1396, 1989

    PubMed  Google Scholar 

  13. Green SB, Byar DP, Walker MDet al.: Comparison of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121–132, 1983

    PubMed  Google Scholar 

  14. Shapiro WR, Green SB, Burger PCet al.: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas. J Neurosurg 71: 1–9, 1989

    Google Scholar 

  15. Sheline GE: Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys 18: 793–803, 1990

    PubMed  Google Scholar 

  16. Burger PC, Vogel FS, Green SBet al.: Glioblastoma multiforme and anaplastic astrocytoma. Cancer 56: 1106–1111, 1985

    PubMed  Google Scholar 

  17. Nelson DF, Curran WJ, Nelson JSet al.: Hyperfractionation in malignant glioma report on a dose searching phase I/II protocol of the Radiation Therapy Oncology Group (RTOG). Proc Am Soc Clin Oncol 9: 90, 1990

    Google Scholar 

  18. Party MRCBTW: Prognostic factors for high grade gliomas: Development of a prognostic index. J Neurocol 9: 47–55, 1990

    Google Scholar 

  19. Burger PC, Green SB: Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617–1625, 1987

    PubMed  Google Scholar 

  20. Byar DP, Green SB, Strike TAet al: Prognostic factors for malignant glioma. Walker MD (ed): Oncology of the Nervous System Boston, MA, Marinus Nijhoff 379–395, 1983

    Google Scholar 

  21. Chang CH, Horton J, Schoenfeld Det al.: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52: 997–1007, 1983

    PubMed  Google Scholar 

  22. Dinapoli RP, Brown LD, Arusell RMet al.: Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade gliomas. J Clin Oncol 11: 1316–1321, 1993

    PubMed  Google Scholar 

  23. Levin VA, Wilson CV, Crafts Det al.: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumor. J Neurosurg 47: 329–335, 1977

    PubMed  Google Scholar 

  24. Macdonald DR, Cascino TL, Clifford S, Schold Jet al.: Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990

    PubMed  Google Scholar 

  25. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J Clin Oncol 2: 1040–1046, 1984

    PubMed  Google Scholar 

  26. Chisholm RA, Stenning S, Hawkins TD: The accuracy of volumetric measurement of high-grade gliomas. Clin Radiol 40: 17–21, 1989

    PubMed  Google Scholar 

  27. Kristiansen K, Hagen S, Kollevold Tet al.: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. A prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47: 649–652, 1981

    PubMed  Google Scholar 

  28. Walker MD, Alexander E, Hunt WEet al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–343, 1978

    PubMed  Google Scholar 

  29. Walker MD, Strike TA, Sheline GE: An analysis of doseeffect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1725–1731, 1979

    PubMed  Google Scholar 

  30. Salazar OM, Rubin P, Feldstein MLet al.: High dose radiation therapy in the treatment of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1733–1740, 1979

    PubMed  Google Scholar 

  31. Party MRCBTW: A Medical Research Council Trial of two radiotherapy doses in the treatment of grade 3 and 4 astrocytoma. Br J Cancer 64: 769–774, 1991

    Google Scholar 

  32. Nelson DF, Diener-West M, Horton Jet al.: Combined modality approach to treatment of malignant gliomas: Reevaluation of RTOG 7401/ECOG 1374 with long-term followup. NCI Monogr 6: 279–284, 1988

    PubMed  Google Scholar 

  33. Leibel SA, Sheline GE: Radiation therapy for neoplasm of the brain. J Neurosurg 66: 1–22, 1987

    PubMed  Google Scholar 

  34. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastomas. Neurology 30: 907–991, 1980

    PubMed  Google Scholar 

  35. Wallner KE, Galicich JH, Krol Get al.: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16: 1405–1409, 1989

    PubMed  Google Scholar 

  36. Gaspar LE, Fisher BJ, Macdonald DRet al.: Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24: 55–57, 1992

    PubMed  Google Scholar 

  37. Leibel SA, Sheline GE: Radiotherapy in the treatment of cerebral astrocytomas, in Thomas DGD (ed): Neuro-oncology Primary Malignant Brain Tumors. London, Edward Arnold 193–221, 1990

    Google Scholar 

  38. Shapiro WR, Green SB, Burger PCet al.: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 71: 1–9, 1989

    Google Scholar 

  39. Garden AS, Maor MH, Yung WKAet al.: Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20: 99–110, 1991

    PubMed  Google Scholar 

  40. Payne D, Simpson WJ, Keen Cet al.: Malignant astrocytoma: Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer 50: 2301–2306, 1982

    PubMed  Google Scholar 

  41. Halperin EC: Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. J Neuro-Oncol 14: 225–262, 1992

    Google Scholar 

  42. Nelson DF, Curran WJJ, Scott Cet al.: Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-possible advantage observed at 72 Gy on 1.2 Gy b.i.d. fractions: Report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Phys 25: 193–207, 1993

    Google Scholar 

  43. Scharfen CO, Sneed PS, Wara WMet al.: High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24: 583–591, 1992

    PubMed  Google Scholar 

  44. Prados MD, Gutin PH, Phillips TLet al.: Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience. Int J Radiat Oncol Biol Phys 24: 593–597, 1992

    PubMed  Google Scholar 

  45. Loeffler JS, Alexander EI, Wen PYet al.: Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 82: 1918–1921, 1990

    PubMed  Google Scholar 

  46. Loeffler JS, Alexander E III, Shea WMet al.: Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10: 1379–1385, 1992

    PubMed  Google Scholar 

  47. Garrett MJ, Hughes HJ, Freeman LS: A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma. Clin Oncol 4: 71–76, 1978

    PubMed  Google Scholar 

  48. Eagan RT, Childs DS, Layton DDet al.: Dianhydrogalactitol and radiation therapy: treatment of supratentorial glioma. JAMA 24: 2046–2050, 1979

    Google Scholar 

  49. Solero CL, Monfardini S, Brambilla Cet al.: Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979: 43–48, 1979

    Google Scholar 

  50. Walker MD, Green SB, Byar DPet al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303: 1323–1329, 1980

    PubMed  Google Scholar 

  51. Fine HA, Dear KBG, Loeffler JSet al.: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993

    PubMed  Google Scholar 

  52. Gelber RD, Goldhirsch A: The concept of an overview of cancer clinical trials with emphasis on early breast cancer. J Clin Oncol 4: 1696–1703, 1986

    PubMed  Google Scholar 

  53. Hunter JE, Schmidt FL: Methods of meta-analysis: correcting error and bias in research findings. Newbury Park, CA: Sage 1990

    Google Scholar 

  54. Levin VA, Wara WM, Davis RLet al.: Phase III comparison of chemotherapy with BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiation therapy with hydroxyurea to patients with malignant gliomas. J Neurosurg 63: 218–223, 1985

    PubMed  Google Scholar 

  55. Levin VA, Wara WM, Davis RLet al.: NCOG protocol 6G91: seven-drug chemotherapy and irradiation for patients with glioblastoma multiforme. Cancer Treat Rep 70: 739–744, 1986

    PubMed  Google Scholar 

  56. Levin VA, Silver P, Hannigan Jet al.: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Rad One Biol Phys 18: 321–324, 1990

    Google Scholar 

  57. Fewer D, Wilson CB, Boldrey EBet al.: The chemotherapy of brain tumors: clinical experience with carmustine (BCNU) and vincristine. JAMA 222: 549–552, 1972

    PubMed  Google Scholar 

  58. Walker MD, Hurwitz BS: BCNU (1.3-bis(2-chloroethyl)-1-nitrosourea: NSC-409962) in the treatment of malignant brain tumora preliminary report. Cancer Chemo Rep 54: 263–271, 1970

    Google Scholar 

  59. Wilson CB, Boldrey EB, Enot KJ: 1.3-Bis(2-chloroethyl)-l-nitrosourea) NSC-409962 in the treatment of brain tumors. Cancer Chemo Rep 54: 273–281, 1970

    Google Scholar 

  60. Stewart DJ, O'Bryan RM, Al-Sarraf Met al.: Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group study. J Neuro-Oncol 1: 145–147, 1983

    Google Scholar 

  61. Grunberg S, Bertram JH, McDermed JEet al.: Treatment of astrocytoma with a 5-day cisplatin infusion. Cancer Drug Delivery 4: 47–53, 1987

    PubMed  Google Scholar 

  62. Walker RW, Dantis E, Shapiro WR: Treatment of recurrent glioma with carboplatin. Proc ASCO 6: 72, 1987

    Google Scholar 

  63. Hirakawa K, Ueda S, Nakagawa Yet al: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976–1981, 1983

    PubMed  Google Scholar 

  64. Longee DC, Friedman HS, Robert E, Albright Jet al.: Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 72: 583–588, 1990

    PubMed  Google Scholar 

  65. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10: 766–771, 1992

    PubMed  Google Scholar 

  66. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360–364, 1988

    PubMed  Google Scholar 

  67. Macdonald DR, Gasper LE, Cairncross JG: Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurology 27: 573–574, 1990

    Google Scholar 

  68. Cairncross G, Macdonald D, Ludwin Set al.: Phase II study of chemotherapy for anaplastic oligodendroglioma (preliminary report). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc Am Soc Clin Oncol 12: 175, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Brigham and Women's Hospital, USA

    Howard A. Fine

  2. The Brain Tumor Centre, Harvard Medical School, Boston, Ma

    Howard A. Fine

Authors
  1. Howard A. Fine
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fine, H.A. The basis for current treatment recommendations for malignant gliomas. J Neuro-Oncol 20, 111–120 (1994). https://doi.org/10.1007/BF01052722

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01052722

Key words

Search

Navigation